{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:50:01Z","timestamp":1791589801996,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The ESCORT-HT study recently demonstrated non-inferiority of esaxerenone to angiotensin II receptor blockers (ARBs) in lowering morning home systolic blood pressure (SBP) in Japanese patients aged \u226565 years with inadequately controlled hypertension on amlodipine. This predefined subgroup analysis of the ESCORT-HT study analyzed age-related differences in the efficacy and safety of esaxerenone relative to ARBs. In the 65\u201374-year subgroup, 98 patients were treated with esaxerenone and 94 with an ARB; in the \u226575-year subgroup, 104 were treated with esaxerenone and 106 with an ARB. The least squares mean difference in morning home SBP between the two treatment groups at end of treatment was \u22121.1 (95%\u00a0confidence interval [CI]\u2009\u22123.8, 1.6) mmHg for the 65\u201374-year subgroup and \u22122.2 (95% CI\u2009\u22125.2, 0.9) mmHg for the \u226575-year subgroup. The upper bound of the 95% CI was within the pre-defined non-inferiority margin of &lt;3.8\u2009mmHg. The urine albumin-to-creatinine ratio decreased in all groups at Week 12, regardless of age or treatment, and N-terminal pro-B-type natriuretic peptide levels decreased in esaxerenone-treated patients, regardless of age. The incidence of treatment-emergent adverse events was 34.3% (esaxerenone) and 32.0% (ARB) in patients 65\u201374 years, and 16.7% and 29.6%, respectively, in patients aged \u226575 years. There were no notable increases in the incidence of hyperkalemia or hypokalemia, relative to ARBs, in any of the age subgroups. This predefined subgroup analysis of the ESCORT-HT study showed antihypertensive effects consistent with the non-inferiority of esaxerenone to ARBs in both age groups, and suggested a potential cardioprotective effect, including for patients aged \u226575 years.<\/jats:p>","DOI":"10.1038\/s41440-026-02757-8","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:01:46Z","timestamp":1791586906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-stratified efficacy and safety of esaxerenone versus angiotensin II receptor blockers in older patients with hypertension: a predefined subanalysis of the ESCORT-HT study"],"prefix":"10.1038","author":[{"given":"Kazuomi","family":"Kario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ohbayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Abiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kodono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Shimosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Shiosakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketoshi","family":"Furugori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ESCORT-HT investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichi","family":"Kurioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuguru","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ohbayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumie","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Inobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daishiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuaki","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Abiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kodono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Hisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Tamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Arino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenei","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Yamato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihiro","family":"Kiyosue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"2757_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.35772\/ghm.2019.01011","volume":"1","author":"H Nakatani","year":"2019","unstructured":"Nakatani H. Population aging in Japan: policy transformation, sustainable development goals, universal health coverage, and social determinates of health. Glob Health Med. 2019;1:3\u201310.","journal-title":"Glob Health Med"},{"key":"2757_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.939103","volume":"9","author":"W Cheng","year":"2022","unstructured":"Cheng W, Du Y, Zhang Q, Wang X, He C, He J, et al. Age-related changes in the risk of high blood pressure. Front Cardiovasc Med. 2022;9:939103.","journal-title":"Front Cardiovasc Med"},{"key":"2757_CR3","unstructured":"Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011\u20132012. NCHS Data Brief. 2013; 1\u20138."},{"key":"2757_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/hr.2010.162","volume":"33","author":"K Hayashi","year":"2010","unstructured":"Hayashi K, Saruta T, Goto Y, Ishii M. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res. 2010;33:1211\u201320. JATOS Study Group.","journal-title":"Hypertens Res"},{"key":"2757_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/ajh\/hpy169","volume":"32","author":"CJ Huang","year":"2019","unstructured":"Huang CJ, Chiang CE, Williams B, Kario K, Sung SH, Chen CH, et al. Effect modification by age on the benefit or harm of antihypertensive treatment for elderly hypertensives: a systematic review and meta-analysis. Am J Hypertens. 2019;32:163\u201374.","journal-title":"Am J Hypertens"},{"key":"2757_CR6","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1161\/HYPERTENSIONAHA.122.19810","volume":"79","author":"K Kario","year":"2022","unstructured":"Kario K, Hasebe N, Okumura K, Yamashita T, Akao M, Atarashi H, et al. Home blood pressure can predict the risk for stroke\/bleeding events in elderly patients with nonvalvular atrial fibrillation from the ANAFIE registry. Hypertension. 2022;79:2696\u2013705.","journal-title":"Hypertension"},{"key":"2757_CR7","unstructured":"Japanese Society of Hypertension Guidelines Committee. The Japanese Society of Hypertension guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025). Tokyo; Life Science Publishing Co., Ltd; 2025 (in Japanese)."},{"key":"2757_CR8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41440-019-0238-2","volume":"42","author":"M Ohishi","year":"2019","unstructured":"Ohishi M, Yoshida T, Oh A, Hiroi S, Takeshima T, Otsuka Y, et al. Analysis of antihypertensive treatment using real-world Japanese data-the retrospective study of antihypertensives for lowering blood pressure (REAL) study. Hypertens Res. 2019;42:1057\u201367.","journal-title":"Hypertens Res"},{"key":"2757_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2165\/00002512-199405050-00007","volume":"5","author":"J Belmin","year":"1994","unstructured":"Belmin J, L\u00e9vy BI, Michel JB. Changes in the renin-angiotensin-aldosterone axis in later life. Drugs Aging. 1994;5:391\u2013400.","journal-title":"Drugs Aging"},{"key":"2757_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/jch.12733","volume":"18","author":"K Kario","year":"2016","unstructured":"Kario K, Hoshide S. Age- and sex-related differences in efficacy with an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensive patients. J Clin Hypertens (Greenwich). 2016;18:672\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2757_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41:1021\u20136.","journal-title":"Hypertension"},{"key":"2757_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","volume":"6","author":"T Saruta","year":"2004","unstructured":"Saruta T, Kageyama S, Ogihara T, Hiwada K, Ogawa M, Tawara K, et al. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens (Greenwich). 2004;6:175\u201383.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2757_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1161\/HYPERTENSIONAHA.114.04935","volume":"65","author":"K Kario","year":"2015","unstructured":"Kario K, Hoshide S. Age-Related Difference in the Sleep Pressure-Lowering Effect Between an Angiotensin II Receptor Blocker and a Calcium Channel Blocker in Asian Hypertensives: The ACS1 Study. Hyperten. 2015;65:729\u201335.","journal-title":"Hyperten"},{"key":"2757_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharm. 2015;761:226\u201334.","journal-title":"Eur J Pharm"},{"key":"2757_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s13318-022-00760-1","volume":"47","author":"SM Jankovi\u0107","year":"2022","unstructured":"Jankovi\u0107 SM, Jankovi\u0107 SV. Clinical pharmacokinetics and pharmacodynamics of esaxerenone, a novel mineralocorticoid receptor antagonist: a review. Eur J Drug Metab Pharmacokinet. 2022;47:291\u2013308.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2757_CR16","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. EXCITE-HT investigators. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u201346.","journal-title":"Hypertens Res"},{"key":"2757_CR17","doi-asserted-by":"crossref","unstructured":"Kario K, Ohbayashi H, Ishii H, Kato M, Nozaki M, Abiru N, et al. Esaxerenone versus angiotensin II receptor blockers as second-line therapy in older Japanese patients with uncontrolled hypertension on calcium channel blockers: The randomized, open-label ESCORT-HT study. Hypertens Res. 2026;49:2240\u201352.","DOI":"10.1038\/s41440-026-02634-4"},{"key":"2757_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41440-024-01887-1","volume":"48","author":"K Kario","year":"2025","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. EXCITE-HT investigators. Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker. Hypertens Res. 2025;48:506\u201318.","journal-title":"Hypertens Res"},{"key":"2757_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14947","volume":"27","author":"K Kario","year":"2025","unstructured":"Kario K, Katsuya T, Shimosawa T, Taguchi T, Tanabe A, Ohishi M. ESCORT-HT investigators. Rationale and design of a randomized, open-label, parallel-group study of esaxerenone versus angiotensin receptor blockers in older patients with uncontrolled hypertension on calcium channel blocker monotherapy (ESCORT-HT). J Clin Hypertens (Greenwich). 2025;27:e14947.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2757_CR20","doi-asserted-by":"crossref","unstructured":"Iwashima Y, Akasaki Y, Ito N, Nozato Y, Takami Y, Okochi J, et al. Consensus statement on practical guidance for optimizing antihypertensive therapy in older adults needing nursing care by the Japan Geriatrics Society and the Japanese Society of Hypertension: English translation of the Japanese article. Hypertens Res. 2026;49:1578\u201385.","DOI":"10.1038\/s41440-026-02551-6"},{"key":"2757_CR21","unstructured":"Esaxerenone (Minnebro) Tablets [Japanese package insert] [In Japanese], Daiichi Sankyo Co., Ltd., Tokyo, Japan; 2024, https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00070243.pdf. Accessed 30 March 2026."},{"key":"2757_CR22","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.4065\/mcp.2011.0437","volume":"86","author":"PM McKie","year":"2011","unstructured":"McKie PM, Cataliotti A, Sangaralingham SJ, Ichiki T, Cannone V, Bailey KR, et al. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc. 2011;86:1154\u201360.","journal-title":"Mayo Clin Proc"},{"key":"2757_CR23","first-page":"741","volume":"15","author":"A Sezai","year":"2025","unstructured":"Sezai A, Abe M, Maruyama T, Taoka M, Sekino H, Tanaka M. A prospective crossover clinical trial of esaxerenone and eplerenone in patients with chronic heart failure complicated by hypertension. Life (Basel). 2025;15:741.","journal-title":"Life (Basel)"},{"key":"2757_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41440-023-01519-0","volume":"47","author":"T Katsuya","year":"2024","unstructured":"Katsuya T, Inobe Y, Uchiyama K, Nishikawa T, Hirano K, Kato M, et al. ENaK investigators. Exploratory study on the relationship between urinary sodium\/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study. Hypertens Res. 2024;47:835\u201348.","journal-title":"Hypertens Res"},{"key":"2757_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41440-025-02412-8","volume":"49","author":"K Kario","year":"2026","unstructured":"Kario K, Ohishi M, Katsuya T, Shimosawa T, Shiosakai K, Furugori T, et al. EXCITE-HT investigators. Effect of N-terminal pro B-type natriuretic peptide levels on the efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of Japanese patients with uncontrolled essential hypertension: a subanalysis of the EXCITE-HT study. Hypertens Res. 2026;49:431\u201343.","journal-title":"Hypertens Res"},{"key":"2757_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","volume":"7","author":"G Savarese","year":"2019","unstructured":"Savarese G, Vedin O, D\u2019Amario D, Uijl A, Dahlstrom U, Rosano G, et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail. 2019;7:306\u201317.","journal-title":"JACC Heart Fail"},{"key":"2757_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","volume":"393","author":"BP Halliday","year":"2019","unstructured":"Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): An open-label, pilot, randomised trial. Lancet. 2019;393:61\u201373.","journal-title":"Lancet"},{"key":"2757_CR28","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","volume":"129","author":"A Basuray","year":"2014","unstructured":"Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, et al. Heart failure with recovered ejection fraction: Clinical description, biomarkers, and outcomes. Circulation. 2014;129:2380\u20137.","journal-title":"Circulation"},{"key":"2757_CR29","doi-asserted-by":"publisher","first-page":"e089783","DOI":"10.1136\/bmjopen-2024-089783","volume":"14","author":"M Guppy","year":"2024","unstructured":"Guppy M, Thomas ET, Glasziou P, Clark J, Jones M, O\u2019Hara DV, et al. Rate of decline in kidney function with age: a systematic review. BMJ Open. 2024;14:e089783.","journal-title":"BMJ Open"},{"key":"2757_CR30","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/ijms23031772","volume":"23","author":"P Bryniarski","year":"2022","unstructured":"Bryniarski P, Nazimek K, Marcinkiewicz J. Immunomodulatory activity of the most commonly used antihypertensive drugs-angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Int J Mol Sci. 2022;23:1772.","journal-title":"Int J Mol Sci"},{"key":"2757_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41440-020-00569-y","volume":"44","author":"H Rakugi","year":"2021","unstructured":"Rakugi H, Yamakawa S, Sugimoto K. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. Hypertens Res. 2021;44:371\u201385.","journal-title":"Hypertens Res"},{"key":"2757_CR32","doi-asserted-by":"publisher","first-page":"318.e9","DOI":"10.1016\/j.amjmed.2017.09.026","volume":"131","author":"N Mattsson","year":"2018","unstructured":"Mattsson N, Nielsen OW, Johnson L, Prescott E, Schnohr P, Jensen GB, et al. Prognostic impact of mild hypokalemia in terms of death and stroke in the general population-a prospective population study. Am J Med. 2018;131:318.e9\u201319.","journal-title":"Am J Med"},{"key":"2757_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s11255-016-1489-3","volume":"49","author":"S Bardak","year":"2017","unstructured":"Bardak S, Turgutalp K, Koyuncu MB, Hari H, Helvaci I, Ovla D, et al. Community-acquired hypokalemia in elderly patients: related factors and clinical outcomes. Int Urol Nephrol. 2017;49:483\u20139.","journal-title":"Int Urol Nephrol"},{"key":"2757_CR34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.53350\/pjmhs22169658","volume":"16","author":"N Yaqoob","year":"2022","unstructured":"Yaqoob N, Butt MAR, Khan FN, Ilyas M, Zaman MH, Khalid F. Prevalance of renal and electrolyte disorders in chronic heart failure patients. Pak J Med Health Sci. 2022;16:658\u201360.","journal-title":"Pak J Med Health Sci"},{"key":"2757_CR35","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.amjmed.2016.01.016","volume":"129","author":"FH Verbrugge","year":"2016","unstructured":"Verbrugge FH, Grodin JL, Mullens W, Taylor DO, Starling RC, Tang WH. Transient hyponatremia during hospitalization for acute heart failure. Am J Med. 2016;129:620\u20137.","journal-title":"Am J Med"},{"key":"2757_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ijcard.2008.05.006","volume":"136","author":"C Adamopoulos","year":"2009","unstructured":"Adamopoulos C, Pitt B, Sui X, Love TE, Zannad F, Ahmed A. Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int J Cardiol. 2009;136:270\u20137.","journal-title":"Int J Cardiol"},{"key":"2757_CR37","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1001\/archsurg.138.10.1055","volume":"138","author":"AE Luckey","year":"2003","unstructured":"Luckey AE, Parsa CJ. Fluid and electrolytes in the aged. Arch Surg. 2003;138:1055\u201360.","journal-title":"Arch Surg"},{"key":"2757_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/pop.2018.0069","volume":"22","author":"R Ofori-Asenso","year":"2019","unstructured":"Ofori-Asenso R, Chin KL, Curtis AJ, Zomer E, Zoungas S, Liew D. Recent patterns of multimorbidity among older adults in high-income countries. Popul Health Manag. 2019;22:127\u201337.","journal-title":"Popul Health Manag"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02757-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:01:47Z","timestamp":1791586907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02757-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":38,"alternative-id":["2757"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02757-8","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KK received honoraria from Daiichi Sankyo Co., Ltd. HO received research funding from Kracie, Ltd. and KYORIN Pharmaceutical Co., Ltd. TK received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., and CureApp, Inc. TS received research funding from SFM Co. Ltd.; consulting fees from Sekisui Medical Co., Ltd. and EPS Co., Ltd.; and honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Otsuka Pharmaceutical Co., Ltd. MO received honoraria from Daiichi Sankyo Co., Ltd. KS, GK, and TT are employees of Daiichi Sankyo Co., Ltd. HI, MK, MNozaki, NA, TF, KN, YF, NI, KU, MNishizawa, YH, NN, SK, and KH have no conflicts to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}